In 2016, ICI were introduced for the treatment of HNSCC, when the anti-PD-1 monoclonal antibodies pembrolizumab and nivolumab received approval from the FDA for the treatment of patients with R/M HNSCC. Here, PDCD1 is linked to head and neck squamous cell carcinoma.